Background With respect to patient-centered care, measuring care effects based on patient-
relevant outcomes is becoming increasingly important. There is some uncertainty about …

Rationale & Objective Trials in autosomal dominant polycystic kidney disease (ADPKD)
have increased, but their impact on decision making has been limited. Because …

The omission of outcomes that are of relevance to patients, clinicians, and regulators across
trials in autosomal dominant polycystic kidney disease (ADPKD) limits shared decision …

Rationale & Objective Outcomes reported in trials involving patients with autosomal
dominant polycystic kidney disease (ADPKD) are heterogeneous and rarely include patient …

Objective To explore how stakeholders in rehabilitation conceptualise 'successful
rehabilitation', to inform the development of a minimum dataset and core outcomes for sub …

Rationale & Objective The inconsistency in outcomes reported and lack of patient-reported
outcomes across trials in children with chronic kidney disease (CKD) limits shared decision …

Patient and caregiver involvement broadens the scope of new knowledge generated from
research and can enhance the relevance, quality and impact of research on clinical practice …

Introduction Tolvaptan, a treatment for autosomal dominant polycystic kidney disease
(ADPKD), inhibits vasopressin V2 receptor signaling, which causes aquaretic adverse …

Objectives Autosomal dominant polycystic kidney disease (ADPKD) is the most common
inherited kidney condition, accounting for 7%–10% of patients with kidney failure …

Patient and caregiver involvement can enhance the uptake and impact of research,
however, the involvement of patients and caregivers who are underserved and marginalized …